Optimization of Lead BKIs for Cryptosporidiosis Therapy

$8.34M USD

Funder	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Recipient Organization	University of Washington
Country	United States
Start Date	Jan 01, 2021
End Date	Dec 31, 2025
Duration	1,825 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`10090142`

Grant Description

ABSTRACT: Optimization of Lead BKIs for Cryptosporidiosis Therapy The broad, long-term objective of this research is to develop a therapeutic for treatment of Cryptosporidium infection. Cryptosporidium infection causes persistent diarrhea (cryptosporidiosis) that is associated with increased morbidity and mortality in children and immunocompromised individuals. Cryptosporidium is one of the most important pathogens leading to poor outcomes in 3-fold mortality and strong associations with stunting and impaired neurological development. The only available therapeutic, nitazoxanide, does not work in immunocompromised individuals and has